Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
ASTRO brain mets guideline: SRS strongly recommended for up to 4 intact mets (ECOG 0-2), conditionally for 5-10; size-tiered SRS dose grid and HA-WBRT plus memantine codified.
A guideline-and-consensus day, no new outcome data. ASTRO (CNS) and ESTRO (spine) codify SRS/SBRT dose by lesion size and BED10, with 2x12Gy conditionally preferred for painful spine mets. Sacral SBRT contouring and pelvic SABR re-RT consensus both left gaps: CTV kappa 0.59, and no agreement on cumulative OAR limits or re-RT interval.
read the full digest โStudies ยท 273
- International consensus: target volume delineation for sacral metastases and spinal SBRTCTV kappa 0.59 vs GTV 0.73 across 9 experts contouring 10 sacral metastasis cases; compartment-based CTV rules and an eight-segment sacral map proposed.
- ESTRO Clinical Practice Guideline: SBRT for Spine Metastases22 recommendations, 5 statements: spine SBRT dose above 1x18Gy (BED10=50Gy10) for LC; 2x12Gy conditionally preferred for painful mets; PTV margin โค3mm.
- International Delphi consensus: pelvic SABR re-irradiation66% of statements reached consensus among 21-23 international radiation oncologists; interval since prior RT, lesion number/size and cumulative OAR limits stayed unresolved.
- ASTRO Clinical Practice Guideline: RT for Brain MetastasesSRS strongly recommended for up to 4 intact brain mets (ECOG 0-2), conditionally for 5-10; size-tiered SRS dose grid and HA-WBRT plus memantine codified.
- GEC-ESTRO HNS critical review: skin superficial brachytherapy with flaps and customized mouldsPrescription >5 mm deep judged acceptable for selected large NMSC using tailored bolus; at 5 mm depth, 5โ10 mm bolus cut skin Dmax 187%โ148%.
- GEC-ESTRO ACROP skin brachytherapy recommendationsConsensus technique guide for skin BT: contact BT for tumours <5 mm deep, interstitial for โฅ5 mm or curved surfaces; no single standard schedule recommended.
- ASTRO guideline: definitive and postoperative RT for BCC/cSCCASTRO grades definitive RT strong for non-surgical BCC/cSCC; PORT strong for cSCC adverse features but only conditional for BCC equivalents.
- Reduced fractionation in lung RT during COVID-19Pandemic-era UK guidance: peripheral SABR 30Gy to 34Gy single fraction; 52Gy/15 fx isoeffective for tumour control vs 55Gy/20 fx (ฮฑ/ฮฒ 10).
- IMWG consensus: cement augmentation for myeloma VCFsoffer BKP or PV within 4-8 weeks for MM pts with significant VCF pain; RT reserved for soft-tissue mass, used sparingly to spare marrow.
- Modeling clinical outcomes in radiotherapy: NTCP, TCP and the TECsPersonal review of TCP/NTCP outcome modeling and the AAPM/ASTRO TEC projects (QUANTEC, HyTEC, PENTEC); no effect size reported in source.
- Biological principles of SBRT/SRS: indirect cell deathNarrative review: doses above ~10 Gy/fraction cause tumor vascular injury and secondary cell death, plus enhanced antitumor immunity, beyond direct cell kill.
- Late effects of RT in children vs adults: QUANTEC, HyTEC, PENTECNo effect size reported in source; pediatric NTCP similar to adults for brain necrosis, optic, parotid, liver, greater for neurocognition, cerebrovascular, lactation, lower for ovary.